On December 7, 2021, The EVERY Company, the leading precision fermentation platform accelerating a global transition to animal-free protein, announced it has closed $175 million in Series C financing. The round was co-led by new investor, McWin, and existing investor, Rage Capital. Other new and existing investors joined the round including Temasek, Grosvenor’s Wheatsheaf Group, and TO Ventures. Prosus Ventures also contributed to the funding, marking its first investment in synthetic biology.

Notably, the Series C round raised by EVERY™ (formerly Clara Foods) was heavily oversubscribed due to strong investor appetite to fill the growing supply gap for animal-free protein and ingredient solutions. The Series C round brings EVERY’s total funding to $233 million.

EVERY™ will use the capital to scale production, commercialize a robust pipeline of animal-free protein products nationwide, and expand into a broad array of new food applications. EVERY™ will also continue to expand its protein production platform by mining the egg proteome for novel, hyper-functional proteins. 

Wilson Sonsini Goodrich & Rosati advised EVERY on corporate and IP matters related to the transaction. The team includes corporate attorneys Andrew Hoffman, Michael Pestana, Ashley Yueh, and Danielle Kassatly and patent attorneys Maya Skubatch and Rex Watkins.

For more information, please see EVERY’s press release.